Get the Stockscreener App
0.72
1.14%
-0.0083
After Hours:
.72
Sangamo Therapeutics Inc stock is traded at $0.72, with a volume of 2.31M.
It is down -1.14% in the last 24 hours and up +9.67% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
See More
Previous Close:
$0.7283
Open:
$0.7104
24h Volume:
2.31M
Relative Volume:
0.37
Market Cap:
$166.35M
Revenue:
$52.29M
Net Income/Loss:
$-134.84M
P/E Ratio:
-0.96
EPS:
-0.75
Net Cash Flow:
$-117.11M
1W Performance:
-2.74%
1M Performance:
+9.67%
6M Performance:
-66.67%
1Y Performance:
+29.54%
1-Day Range:
$0.7008
$0.7422
1-Week Range:
$0.6901
$0.7869
52-Week Range:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.72 | 166.35M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Sangamo Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
5 Best Stem Cell Companies to Invest In (May 2025) - Securities.io
Press Release Distribution & PR Platform - ACCESS Newswire
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
Sangamo Therapeutics to Present Neurology Pipeline Advances at t - GuruFocus
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Business Wire
Sangamo Therapeutics, Inc. (SGMO) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa
Sangamo announces capsid license agreement with Eli Lilly - MSN
Lilly, Sangamo Enter Capsid License Agreement - Contract Pharma
Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech
Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha
Sangamo Thera enters critical deal with Lilly - The Pharma Letter
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace
Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com India
RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga
Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus
Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa
Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada
Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals
Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener
Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga
Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener
Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com
Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
10 Promising Biotech Stocks to Invest in (May 2025) - Securities.io
Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com
Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Fabry Disease Market Growth Projections 2023-2032: - openPR
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa
Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India
Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa
8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga
IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa
Sangamo: Q4 Earnings Snapshot - mySA
Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):